Tectonic Therapeutic, Inc.
NASDAQ:TECX · NASDAQ Global Market
-$0.29 today
Vol 0.10M · Avg 0.20M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:TECX · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$83.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-4.46, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $63.5M +53.5% | $41.4M +11.9% | $37.0M +44.1% | $25.7M +133.7% | $11.0M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.5M +23.4% | $16.7M +116.8% | $7.7M +7.1% | $7.2M +54.9% | $4.6M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $84.0M +44.9% | $58.0M +29.9% | $44.6M +36.0% | $32.8M +110.3% | $15.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.4M -16.4% | $1.6M +11.3% | $1.5M +46.9% | $1.0M +176.4% | $364.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$71.5M -27.1% | -$56.2M -36.5% | -$41.2M -32.8% | -$31.0M -282.2% | -$8.1M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$84.0M -44.9% | -$58.0M -29.9% | -$44.6M -36.0% | -$32.8M -110.3% | -$15.6M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $11.3M +165.1% | $4.3M +633.4% | $581.0K +289.9% | $149.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $63.0K -41.1% | $107.0K -29.6% | $152.0K +5.6% | $144.0K -35.7% | $224.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $11.1M +33581.8% | $33.0K -98.2% | $1.8M +180.8% | $650.0K -90.3% | $6.7M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$72.9M -25.8% | -$58.0M -35.4% | -$42.8M -33.1% | -$32.2M -260.5% | -$8.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.2M | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$74.2M -27.9% | -$58.0M -35.4% | -$42.8M -33.1% | -$32.2M -260.5% | -$8.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$4 -3.1% | -$4 +66.1% | -$12 +60.1% | -$29 +12.9% | -$33 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$4 -3.1% | -$4 +65.9% | -$12 +60.3% | -$29 +12.9% | -$33 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $18.3M +24.1% | $14.8M +299.8% | $3.7M +1.3% | $3.6M +2.1% | $3.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $18.3M +24.1% | $14.8M +297.6% | $3.7M +1.9% | $3.6M +2.1% | $3.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$868.76M
Alto Neuroscience, Inc.
NYSE:ANRO
$779.79M
DBV Technologies S.A.
NASDAQ:DBVT
$383.25M
Amarin Corporation plc
NASDAQ:AMRN
$337.34M
Silence Therapeutics plc
NASDAQ:SLN
$324.73M
Cellectis S.A.
NASDAQ:CLLS
$316.31M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$301.66M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$297.79M
AC Immune S.A.
NASDAQ:ACIU
$240.69M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$117.02M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TECX generate?
Tectonic Therapeutic, Inc. (TECX) reported $0.00 of revenue in fiscal 2025.
Is TECX profitable?
Tectonic Therapeutic, Inc. (TECX) reported -$74,151,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.